Home Clinical and Healthcare Professional Hub Clinical Research Publications Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or IMPT for patients with nasal cavity and paranasal sinus malignancies

09 / 06 / 21

Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or IMPT for patients with nasal cavity and paranasal sinus malignancies


Abstract

Background: Proton therapy (PT) improves outcomes in patients with nasal cavity (NC) and paranasal sinus (PNS) cancers. Herein, the authors have reported to their knowledge the largest series to date using intensity-modulated proton therapy (IMPT) in the treatment of these patients.

Methods: Between 2013 and 2018, a total of 86 consecutive patients (68 of whom were radiation-naive and 18 of whom were re-irradiated) received PT to median doses of 70 grays and 67 grays relative biological effectiveness, respectively. Approximately 53% received IMPT.

Results: The median follow-up was 23.4 months (range, 1.7-69.3 months) for all patients and 28.1 months (range, 2.3-69.3 months) for surviving patients. The 2-year local control (LC), distant control, disease-free survival, and overall survival rates were 83%, 84%, 74%, and 81%, respectively, for radiation-naive patients and 77%, 80%, 54%, and 66%, respectively for re-irradiated patients. Among radiation-naive patients, when compared with 3-dimensional conformal proton technique, IMPT significantly improved LC (91% vs 72%; P < .01) and independently predicted LC (hazard ratio, 0.14; P = .01). Sixteen radiation-naive patients (24%) experienced acute grade 3 toxicities; 4 (6%) experienced late grade 3 toxicities (osteoradionecrosis, vision loss, soft-tissue necrosis, and soft tissue fibrosis) (grading was performed according to the National Cancer Institute Common Terminology Criteria for Adverse Events [version 5.0]). Slightly inferior LC was noted for patients undergoing reirradiation with higher complications: 11% experienced late grade 3 toxicities (facial pain and brain necrosis). Patients treated with reirradiation had more grade 1 to 2 radionecrosis than radiation-naive patients (brain: 33% vs 7% and osteoradionecrosis: 17% vs 3%).

Conclusions: PT achieved remarkable LC for patients with nasal cavity and paranasal sinus cancers with lower grade 3 toxicities relative to historical reports. IMPT has the potential to improve the therapeutic ratio in these malignancies and is worthy of further investigation.

Fan M, Kang JJ, Lee A, Fan D, Wang H, Kitpanit S, Fox P, Sine K, Mah D, McBride SM, Tsai CJ, Riaz N, Dunn LA, Sherman EJ, Michel L, Singh B, Ganly I, Wong RJ, Boyle JO, Cohen MA, Lee NY. Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies. Cancer. 2020 Jan 1;126(9):1905-1916. doi: 10.1002/cncr.32776. Epub 2020 Feb 25. PMID: 32097507; PMCID: PMC7304541.

*Please refer to the Terms and Conditions of this website when leaving the site and viewing third party content. 

Consultants we currently work with (head & neck)

Dr Eleanor Aynsley

Dr Aynsley graduated from Leeds Medical School in 1999. She did medical training in Durham, gaining MRCP in 2004. She...

Read more
Dr Eleanor Aynsley

Dr Shanmugasundaram Ramkumar

Dr Ramkumar is a Consultant Clinical Oncologist specialising in non-surgical treatment of Head and Neck cancer, Skull Base Tumours and...

Read more
Dr Shanmugasundaram Ramkumar

Dr Cheng Boon

Dr Cheng Boon is Consultant Clinical Oncologist at the Worcester Oncology Centre at Worcester Royal Hospital. He completed medical training...

Read more
Dr Cheng Boon

Dr Russell Banner

Dr Russell Banner is a Consultant Clinical Oncologist based in South Wales. His undergraduate training was at Christ’s College, Cambridge...

Read more
Dr Russell Banner

Dr Muthiah Sivaramalingam

Dr Muthiah Sivaramalingam has been a consultant in Clinical Oncology since 2007 and has been Principal Investigator for many clinical...

Read more
Dr Muthiah Sivaramalingam

Dr Josef Kovarik

Dr Josef Kovarik is an acting consultant clinical oncologist and a Lead of ENT Oncology at the Northern Centre for Cancer...

Read more
Dr Josef Kovarik

Cancer treatments we offer

The Rutherford Cancer Centres provide high-quality cancer care by offering access to innovative and advanced treatment techniques using leading technology.

Consultants we work with

We provide exceptional patient support from diagnosis through to treatment and recovery, with leading consultants available at our centres across the country.

Centres across the UK

The Rutherford Cancer Centres provide cancer treatments and other healthcare services across the UK with our centres designed to put the patient experience first.

Contact Us

Get in Touch

If you'd like to speak to us about any of the treatments we offer please don’t hesitate to get in touch. Call us on 0800 210 0402 or

Our Trusted Healthcare Partners